香港全港性血液传播与肠道传播病毒性肝炎流行病学研究
甲肝抗体阳性率65.2%,戊肝抗体阳性率33.3%。
要点
- HBsAg血清流行率7.8%,接种乙肝疫苗与HBsAg阳性风险显著降低相关(OR 0.15)。
- HBsAg阴性者中抗-HBc流行率随年龄从5.4%升至60.1%,提示免疫抑制时HBV再激活风险。
- 抗-HCV阳性率0.5%,未检出HDV;甲肝抗体65.2%,戊肝抗体33.3%。
核心结论
- 尽管普遍接种乙肝疫苗,香港HBV血清流行率仍较高。
- 高抗-HBc流行率提示深度免疫抑制期间HBV再激活的潜在问题。
- HCV和HDV感染仍不常见,甲肝抗体流行率下降而戊肝抗体流行率上升。
研究设计与样本
- 收集基线数据和危险因素,检测甲至戊型肝炎血清学,包括HBsAg阳性者的HBeAg、抗-HBe、抗-HDV和HBV DNA,以及HBsAg阴性者的抗-HBs和抗-HBc。
- 对抗-HCV阳性者检测HCV RNA和基因型。
主要发现
- HBsAg阴性参与者中,抗-HBc血清流行率从<26岁组的5.4%升至>65岁组的60.1%。
- 抗-HAV流行率为65.2%(95%CI 64.2%-66.1%),抗-HEV流行率为33.3%(95%CI 32.4%-34.2%),两者受年龄、家庭收入和在中国大陆出生影响。
临床怎么用
- 对HBsAg阴性但抗-HBc阳性者,在接受深度免疫抑制治疗前应评估HBV再激活风险。
- 香港一般人群中HCV和HDV感染不常见,但甲肝和戊肝抗体流行率受年龄、家庭收入和出生地影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Viral hepatitis epidemiological data are important for the World Health Organization plan of eliminating viral hepatitis. We aimed to document the prevalence of viral hepatitis A to E in Hong Kong. METHODS: This community-based study was open to all Hong Kong Chinese citizens aged ≥18 years. Baseline data and risk factors were collected. Hepatitis A-E serology was measured, including hepatitis B e antigen, antibodies to hepatitis B e antigen, antibodies to hepatitis D, hepatitis B virus (HBV) DNA for hepatitis B surface antigen (HBsAg)-positive participants, and antibodies to hepatitis B surface antigen and antibodies to hepatitis B core antigen (anti-HBc) in HBsAg-negative participants. Hepatitis C virus (HCV) RNA and genotypes were determined in anti-HCV-positive participants. RESULTS: A total of 10 256 participants were recruited from February 2015 to July 2016. Overall HBsAg seroprevalence was 7.8% (95% confidence interval [CI], 7.3%-8.3%), which was reduced significantly with HBV vaccination (odds ratio, 0.15 [95% CI, .11-.21]). Among HBsAg-negative participants, anti-HBc seroprevalence increased from 5.4% (<26 years) to 60.1% (>65 years). No hepatitis D virus (HDV) cases were detected. Anti-HCV positivity was 0.5% (95% CI, .3%-.6%). Prevalence of antibodies to hepatitis A virus (anti-HAV) and hepatitis E virus (anti-HEV) was 65.2% (95% CI, 64.2%-66.1%) and 33.3% (95% CI, 32.4%-34.2%), respectively, and were influenced by age, family income, and being born in mainland China. CONCLUSIONS: HBV seroprevalence remained high despite universal vaccination. High anti-HBc seroprevalence underlines the potential issue of HBV reactivation during profound immunosuppression. HCV and HDV remained uncommon. Anti-HAV seroprevalence had decreased whereas anti-HEV seroprevalence had risen.
引用
- Liu KSH, Seto WK, Lau EHY, et al. A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. J Infect Dis. 2019. PMID: 30668746. doi:10.1093/infdis/jiz038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。